What would you like to look for?
Site search

26 October 2022

Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, recently closed an USD 35 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative.

VISCHER acted as legal advisor to Anokion in this transaction. The team included Matthias Staehelin, Vincent Reardon and Luzius Zumstein (all Corporate/M&A).

Categories: Corporate and Commercial, Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk


You are currently offline. Some pages or content may fail to load.